HUTCHMED says China regulator grants conditional approval for ORPATHYS in MET-amplified gastric cancer
PUBT · 2d ago
Share
Listen to the news
- China’s NMPA granted conditional approval for ORPATHYS (savolitinib) to treat MET-amplified advanced gastric or gastroesophageal junction cancer.
- Use covers patients who failed at least two prior systemic treatments, expanding ORPATHYS to a third approved indication in China.
- Approval was backed by a China Phase II study showing a 32.3% objective response rate, with median duration of response 9.7 months.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607020430PRIMZONEFULLFEED9756041) on July 02, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved